DESOXIMETASONE
Clinical safety rating: safe
Animal studies have demonstrated safety
Desoximetasone is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis. This leads to anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Desoximetasone is metabolized in the liver and skin via phase I (hydroxylation, reduction) and phase II (conjugation) pathways. Enzymes involved include CYP3A4 (minor) and glucuronosyltransferases. |
| Excretion | Primarily renal (urinary) as inactive metabolites, with less than 5% unchanged drug. Fecal excretion accounts for a minor fraction, primarily via bile. |
| Half-life | Terminal elimination half-life is approximately 1.5–2 hours. Due to its topical use, systemic half-life is less clinically relevant; however, prolonged use on large areas or under occlusion may lead to systemic accumulation. |
| Protein binding | Approximately 90–95% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Not well-characterized for topical use; intravenous studies in animals suggest a volume of distribution of approximately 1 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical: Systemic bioavailability is low (<5% in intact skin) but increases with skin barrier disruption, prolonged use, or large treatment areas. Oral bioavailability is negligible due to first-pass metabolism. |
| Onset of Action | Topical: Relief of inflammation and pruritus typically begins within a few hours of application, with maximum effect observed after 1–2 days of regular use. |
| Duration of Action | Topical: Duration of anti-inflammatory effect is approximately 6–8 hours, necessitating twice-daily application for sustained symptom control. Effect may last longer under occlusive dressing. |
Apply a thin film to affected skin areas twice daily.
| Dosage form | CREAM |
| Renal impairment | No specific dose adjustment required for renal impairment. |
| Liver impairment | No specific dose adjustment required for hepatic impairment. |
| Pediatric use | Apply a thin film to affected areas twice daily; use lowest potency and shortest duration possible due to increased systemic absorption. |
| Geriatric use | Use with caution; apply sparingly to limited areas due to increased risk of skin atrophy and systemic effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Systemic absorption can occur with extensive use.
| Breastfeeding | Systemically administered corticosteroids appear in human breast milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration could result in sufficient systemic absorption to produce detectable quantities in breast milk. Caution should be exercised when desoximetasone is administered to a nursing woman. M/P ratio: Not determined. |
| Teratogenic Risk | Desoximetasone is a topical corticosteroid. Systemic absorption is low but may increase with prolonged use over large areas, occlusive dressings, or damaged skin. Animal studies with corticosteroids have shown teratogenicity (cleft palate, intrauterine growth retardation). There are no adequate and well-controlled studies in pregnant women; however, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Risk cannot be ruled out, avoid use if possible. Second and third trimesters: Use with caution, especially with prolonged or widespread application, due to potential for fetal growth restriction and adrenal suppression. |
■ FDA Black Box Warning
None.
| Common Effects | Skin atrophy |
| Serious Effects |
["Hypersensitivity to desoximetasone or any component of the formulation","Untreated bacterial, fungal, viral, or parasitic skin infections","Rosacea","Perioral dermatitis"]
| Precautions | ["Systemic absorption may cause reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria.","Prolonged use may produce atrophy of the skin, striae, and telangiectasias.","Avoid use on infected lesions; if infection develops, discontinue and use appropriate antimicrobial therapy.","Not for ophthalmic or oral use.","Pediatric patients may be more susceptible to systemic toxicity due to higher skin surface-to-body weight ratio.","Use with caution in patients with impaired hepatic function."] |
Loading safety data…
| Fetal Monitoring | If used during pregnancy, monitor for maternal adrenal suppression, especially with prolonged or widespread use. Fetal monitoring may include assessment of growth parameters (ultrasound) if prolonged high-dose therapy is necessary. Newborns exposed in utero should be monitored for adrenal insufficiency and growth retardation. |
| Fertility Effects | No human studies on fertility effects. Animal studies have not reported impairment of fertility. |